Patent ID: 8748484

Claim:
An anti-cancer ruthenium complex having formula 1: wherein: R 1 independently represents —H, —CH 3 , or —CH 2 CH 3 ; R 2 independently represents —H, —CH 3 , —CH 2 CH 3 , —CH 2 OH, —CH 2 SH, —SCH 3 , —SCH 2 CH 3 , —OCH 3 , —OCH 2 CH 3 , —S-carbocycloalkyl, —O-carbocycloalkyl, —S-aryl, —O-aryl, —S-benzyl, —O-benzyl, or —C(O)NHCH 2 aryl; n independently represents 0 or 1; when n represents 1, X independently represents O, S, or NR 3 ; when n represents 0, a single bond exists between the two carbon atoms adjacent to (X) R 3 independently represents —H, —CH 3 , or —CH 2 CH 3 ; Y independently represents O or S Z independently represents O, S, or NR 4 : R 4 independently represents —H or —CH 3 ; L represents a carbonyl, Ph 3 P, imidazole, thiazole, oxazole, or indazole moiety; or an N-heterocyclic carbene moiety selected from the group consisting of 1,3-imidazol-2-ylidene substituted independently at 1,3 atoms; 1,2,4-triazol-5-ylidene substituted independently at 1,4 atoms; or 1,2,3-triazol-5-ylidene substituted independently at 1,4 atoms; wherein the N-heterocyclic carbene moiety is substituted by a substituent selected independently from the group consisting of aryl, benzyl, C 1-6 alkyl, or cyclohexyl; aryl is selected from the group consisting of phenyl or a 5 or 6 member heterocyclic aromatic ring comprising at least one ring heterocyclic atom or group selected from the group consisting of —O—, —S—, —NH—, or —NCH 3 —; carbocycloalkyl groups are 5 or 6 member non-aromatic carbocyclic rings; aryl and carbocycloalkyl groups independently are unsubstituted, or are substituted at any position with one or more substituents; aryl substituents independently are R 10 , —OR 11 , —SR 11 , —N(R 11 ) 2 , R 10 C(O)—, nitro, or halo (F, Cl, or Br), wherein R 10 independently represents aryl, C 1-6 alkyl or cyclohexyl; and R 11 independently represents H, aryl, C 1-6 alkyl or cyclohexyl; and carbocycloalkyl substituents independently are C 1-6 alkyl.